Stifel Nicolaus Forecasts Strong Price Appreciation for Pulmonx (NASDAQ:LUNG) Stock

Posted by George Bondi on Oct 28th, 2026

Pulmonx (NASDAQ:LUNG – Get Free Report) had its target price lifted by analysts at Stifel Nicolaus from $2.50 to $4.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus‘s price objective suggests a potential upside of 52.38% from the company’s previous close.

Several other equities research analysts also recently commented on the company. Weiss Ratings upgraded Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Canaccord Genuity Group set a $5.00 price target on Pulmonx in a report on Wednesday. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $7.67.

View Our Latest Research Report on Pulmonx

Pulmonx Trading Up 32.6%

Shares of Pulmonx stock traded up $0.65 during trading hours on Wednesday, hitting $2.62. The company’s stock had a trading volume of 5,371,230 shares, compared to its average volume of 495,513. Pulmonx has a 1-year low of $1.13 and a 1-year high of $2.77. The business has a fifty day moving average of $2.02 and a 200 day moving average of $1.65. The company has a market capitalization of $112.74 million, a PE ratio of -2.27 and a beta of 0.33. The company has a quick ratio of 3.52, a current ratio of 4.32 and a debt-to-equity ratio of 0.95.

Pulmonx (NASDAQ:LUNG – Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.07. The company had revenue of $22.84 million for the quarter, compared to analyst estimates of $21.93 million. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%. As a group, equities analysts forecast that Pulmonx will post -1.05 EPS for the current year.

Insiders Place Their Bets

In other news, General Counsel David Lehman sold 14,334 shares of Pulmonx stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $32,394.84. Following the sale, the general counsel directly owned 361,827 shares of the company’s stock, valued at approximately $817,729.02. The trade was a 3.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Glendon E. French III sold 41,882 shares of Pulmonx stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total value of $94,653.32. Following the sale, the chief executive officer directly owned 1,137,936 shares in the company, valued at approximately $2,571,735.36. The trade was a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 78,340 shares of company stock worth $177,048 in the last quarter. 7.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pulmonx

A number of hedge funds have recently bought and sold shares of the business. Engineers Gate Manager LP increased its holdings in Pulmonx by 11.5% during the 2nd quarter. Engineers Gate Manager LP now owns 62,589 shares of the company’s stock worth $81,000 after purchasing an additional 6,438 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Pulmonx by 122.5% during the second quarter. Squarepoint Ops LLC now owns 183,558 shares of the company’s stock worth $239,000 after buying an additional 101,066 shares in the last quarter. Hsbc Holdings PLC increased its stake in shares of Pulmonx by 1,275.8% in the second quarter. Hsbc Holdings PLC now owns 193,846 shares of the company’s stock worth $249,000 after buying an additional 179,756 shares during the last quarter. Stonepine Capital Management LLC acquired a new stake in Pulmonx in the second quarter valued at $1,060,067. Finally, Jefferies Financial Group Inc. acquired a new stake in Pulmonx in the second quarter valued at $371,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Key Pulmonx News

Here are the key news stories impacting Pulmonx this week:

Positive Sentiment: Q3 results exceeded expectations: Pulmonx reported adjusted earnings of a $0.19-per-share loss, narrower than the $0.26 loss analysts expected and improved from a $0.34 loss a year earlier. Revenue rose 6% year over year to $22.8 million, ahead of the $21.9 million consensus estimate. Pulmonx Corporation Reports Q3 Loss, Tops Revenue Estimates
Positive Sentiment: Improving operating metrics: U.S. revenue increased 7% to $14.9 million, international revenue grew 5% to $7.9 million, gross margin reached 76%, and operating expenses declined 18% to $24.9 million. The company also maintained its full-year 2026 revenue outlook of $90 million to $92 million and operating-expense guidance of $108 million to $109 million. Pulmonx Reports Third Quarter 2026 Financial Results
Positive Sentiment: Buy rating reiterated: Canaccord maintained its Buy rating on LUNG, reinforcing the bullish interpretation of the earnings report. Canaccord Reiterates Buy Rating on Pulmonx
Neutral Sentiment: Pulmonx ended September with $52.7 million in cash and reiterated its outlook, but it remains unprofitable and expects a full-year loss.
Negative Sentiment: Reported insider-trading data showed no insider purchases and multiple executive sales over the past six months, a potential cautionary signal for investors.

About Pulmonx

(Get Free Report)

Pulmonx Corporation is a medical device company focused on developing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company’s technologies are designed to reduce hyperinflation in damaged portions of the lung and help improve breathing, exercise capacity and quality of life.

Pulmonx’s primary product is the Zephyr Endobronchial Valve, a bronchoscopically implanted, one-way valve intended for certain patients with severe emphysema.